KalVista Pharmaceuticals (KALV) Misses Q1 EPS by 16c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($1.12), $0.16 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $1.43 million versus the consensus estimate of $951.67 thousand.

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• XORTX to voluntarily delist from TSX Venture Exchange
• Circle board member resigns after nearly 13 years of service